GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Consensus Price Target of $55.33 According to Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have received an average rating of “Hold” from the nineteen brokerages that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $55.33.

A number of equities analysts have weighed in on GSK shares. HSBC restated a “hold” rating on shares of GSK in a research report on Thursday, September 10th. Berenberg Bank reiterated a “buy” rating on shares of GSK in a research report on Tuesday, October 6th. Deutsche Bank Aktiengesellschaft reissued a “neutral” rating on shares of GSK in a research note on Tuesday, September 29th. Royal Bank Of Canada initiated coverage on shares of GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Finally, Weiss Ratings lowered shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th.

GSK Price Performance

Shares of GSK stock opened at $50.74 on Tuesday. The firm has a market cap of $102.64 billion, a PE ratio of 15.87, a P/E/G ratio of 2.28 and a beta of 0.33. GSK has a twelve month low of $42.85 and a twelve month high of $61.69. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The business has a 50-day moving average price of $49.59 and a 200 day moving average price of $51.45.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same period last year, the company earned $0.47 earnings per share. GSK’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts predict that GSK will post 4.78 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a dividend of $0.4515 per share. This is an increase from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. This represents a $1.81 annualized dividend and a yield of 3.6%. GSK’s dividend payout ratio (DPR) is presently 55.31%.

Institutional Trading of GSK

A number of institutional investors have recently made changes to their positions in GSK. Total Wealth Planning & Management Inc. grew its holdings in shares of GSK by 4.7% during the third quarter. Total Wealth Planning & Management Inc. now owns 16,414 shares of the pharmaceutical company’s stock worth $791,000 after buying an additional 735 shares in the last quarter. Invested Advisors raised its position in shares of GSK by 15.6% in the third quarter. Invested Advisors now owns 5,788 shares of the pharmaceutical company’s stock valued at $279,000 after buying an additional 781 shares during the last quarter. Mondrian Investment Partners LTD lifted its stake in shares of GSK by 1.1% in the third quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company’s stock worth $239,210,000 after buying an additional 55,116 shares in the last quarter. Evergreen Capital Management LLC boosted its position in GSK by 16.5% during the third quarter. Evergreen Capital Management LLC now owns 39,205 shares of the pharmaceutical company’s stock worth $1,907,000 after acquiring an additional 5,541 shares during the last quarter. Finally, Gibbs Wealth Management grew its stake in GSK by 13.8% during the 3rd quarter. Gibbs Wealth Management now owns 15,543 shares of the pharmaceutical company’s stock valued at $749,000 after acquiring an additional 1,881 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.